Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300885 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 926
- Enrollment target
NCT00300885 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 926 participants.
The verdict
NCT00300885, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 926 participants
- Enrollment target
Study Summary
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
- DRUG Carboplatin plus Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 926 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300885
The ClinicalTrials.gov registry entry for NCT00300885 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 926 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel is the first listed.
NCT00300885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300885 about?
NCT00300885 is a clinical study titled "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)". A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
What is the current status of trial NCT00300885?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 926 participants. The study started on 2006-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00300885?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel (DRUG), Carboplatin plus Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00300885?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.